A newer antimalaria medication with a simplified dosing regimen may be useful in US patients as prophylaxis or as an antirelapse treatment, according to a review in the Morbidity and Mortality Weekly Report.
The US Food and Drug Administration approved tafenoquine in 2018 as prophylaxis for individuals traveling to malaria-endemic areas and for antirelapse therapy for people infected with the Plasmodium vivax malaria parasite. Previously, only primaquine was available for antirelapse therapy.
Kuehn B. New Malaria Option. JAMA. 2020;323(2):112. doi:10.1001/jama.2019.20669
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: